International Research Journal of Human Resource and Social Sciences
ISSN(O): (2349-4085) ISSN(P): (2394-4218)
Impact Factor 6.924 Volume 9, Issue 11, November 2022
Website- www.aarf.asia, **Email** : editoraarf@gmail.com

GALECTIN-3 AND GDF-15 AS POTENTIAL BIOMARKERS FOR EARLY IDENTIFICATION OF DIABETIC KIDNEY DISEASE IN PATIENTS: A COMPREHENSIVE REVIEW

BHOOPENDRA PATIDAR
RESEARCH SCHOLAR SUNRISE UNIVERSITY ALWAR

DR. VIVEK GUPTA
ASSOCIATE PROFESSOR SUNRISE UNIVERSITY ALWAR

ABSTRACT

Diabetic kidney disease (DKD) is a common complication of diabetes mellitus and a leading cause of end-stage renal disease. Early identification of DKD is crucial for implementing timely interventions to prevent disease progression. Current diagnostic methods for DKD primarily rely on measuring albuminuria and estimating glomerular filtration rate. However, these markers may not accurately detect early-stage kidney damage. This research paper aims to explore the potential of galectin-3 and growth differentiation factor-15 (GDF-15) as biomarkers for the early identification of DKD in patients. The paper will provide an overview of DKD pathogenesis, discuss the roles of galectin-3 and GDF-15 in kidney disease, review existing evidence on their diagnostic potential, and highlight their possible utility in clinical practice.

Keywords: - Diabetic, Kidney, Disease, Mellitus, Galectin.

INTRODUCTION

Diabetic kidney disease (DKD), also known as diabetic nephropathy, is a progressive renal complication that affects a significant proportion of individuals with diabetes mellitus. It is one of the leading causes of end-stage renal disease (ESRD) worldwide. DKD is characterized by structural and functional abnormalities of the kidneys, including glomerular and tubular damage, albuminuria, and declining renal function.

Early identification of DKD is crucial for implementing appropriate therapeutic interventions aimed at slowing disease progression and preventing the development of ESRD. Currently, the diagnosis of DKD primarily relies on the measurement of albuminuria and the estimation of

glomerular filtration rate (GFR). However, these markers may not be sensitive or specific enough to detect early-stage kidney damage, limiting their effectiveness in identifying individuals at risk of DKD.

1. Diabetic Kidney Disease (DKD): Pathogenesis and Clinical Implications

The pathogenesis of DKD is complex and multifactorial, involving a combination of metabolic, hemodynamic, and inflammatory factors. Hyperglycemia-induced metabolic abnormalities, such as increased oxidative stress, activation of the renin-angiotensin-aldosterone system, and the accumulation of advanced glycation end products (AGEs), contribute to the development and progression of DKD. Inflammatory processes, including the activation of pro-inflammatory cytokines and chemokines, also play a significant role in renal damage.

The clinical implications of DKD are substantial, as it significantly increases the risk of cardiovascular events and mortality. DKD is associated with a higher prevalence of hypertension, dyslipidemia, and an increased likelihood of developing other diabetic complications, such as retinopathy and neuropathy. Therefore, early identification and management of DKD are critical not only for preserving renal function but also for mitigating the overall burden of diabetes-related complications.

2. Importance of Early Identification of DKD

Early detection of DKD allows for timely implementation of interventions to slow disease progression and prevent the development of ESRD. Early stages of DKD, characterized by subtle renal histological changes and minimal albuminuria, may be reversible with appropriate therapeutic strategies. Effective management strategies, including glycemic control, blood pressure regulation, and the use of renoprotective medications such as angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs), can significantly delay the onset and progression of DKD. Furthermore, early identification of DKD enables the opportunity for enrollment in clinical trials evaluating novel therapeutic agents and interventions.

Given the limitations of current diagnostic markers, there is a need to explore novel biomarkers that can accurately detect early renal damage in individuals with diabetes. Galectin-3 and growth differentiation factor-15 (GDF-15) have emerged as potential biomarkers for DKD, showing promise in providing early identification and risk stratification. Understanding the role of galectin-3 and GDF-15 in DKD pathogenesis and their diagnostic potential can contribute to the development of more effective strategies for early detection and intervention in DKD patients.

GALECTIN-3

1. Galectin-3: Biology and Function

Galectin-3 is a member of the galectin family, a group of carbohydrate-binding proteins with diverse biological functions. It is a soluble lectin that can be found in various tissues and cell types, including the kidney. Galectin-3 plays a role in multiple physiological and pathological processes, such as cell adhesion, immune response modulation, inflammation, and fibrosis.

The function of galectin-3 in diabetic kidney disease is multifaceted. It has been implicated in the development and progression of renal fibrosis, a key pathological feature of DKD. Galectin-3 promotes fibrogenesis by stimulating the activation of renal fibroblasts, deposition of extracellular matrix proteins, and recruitment of inflammatory cells. It also contributes to the activation of profibrotic signaling pathways, including transforming growth factor-beta (TGF-β) and connective tissue growth factor (CTGF).

2. Galectin-3 in Diabetic Kidney Disease

In DKD, galectin-3 expression is upregulated in the renal tubular epithelial cells, mesangial cells, and interstitial cells. Experimental studies have demonstrated that increased galectin-3 levels correlate with the severity of renal fibrosis and albuminuria in diabetic animal models. Clinical studies have also shown elevated galectin-3 levels in the urine and serum of DKD patients compared to individuals with diabetes but without kidney involvement.

3. Galectin-3 as a Biomarker for Early Identification of DKD

Galectin-3 has shown promise as a biomarker for early identification of DKD. Studies have reported an association between increased galectin-3 levels and the presence of early renal dysfunction, even in individuals with normal albumin excretion. Galectin-3 has been found to predict the progression of DKD, including the development of albuminuria and decline in renal function.

Several studies have demonstrated the diagnostic accuracy of galectin-3 in distinguishing DKD patients from individuals with diabetes but without kidney involvement. Galectin-3 levels have been shown to correlate with histological features of renal damage, such as glomerular sclerosis and interstitial fibrosis. Moreover, galectin-3 has shown potential as a prognostic biomarker, as higher levels have been associated with an increased risk of cardiovascular events and mortality in DKD patients.

4. Mechanisms Underlying Galectin-3's Role in DKD Progression

The exact mechanisms by which galectin-3 promotes DKD progression are not fully understood. However, experimental evidence suggests that galectin-3 may contribute to renal fibrosis through various pathways. It can interact with specific glycoproteins, extracellular matrix components, and cell surface receptors, leading to the activation of profibrotic signaling cascades. Galectin-3-

mediated inflammation and immune cell recruitment may also contribute to the development of renal fibrosis in DKD.

In addition to its direct effects on fibrosis, galectin-3 may have indirect effects on DKD progression by influencing other pathological processes, such as oxidative stress, endothelial dysfunction, and vascular remodeling. Further research is needed to elucidate the precise molecular mechanisms underlying the role of galectin-3 in DKD and its potential as a therapeutic target.

Overall, galectin-3 holds promise as a biomarker for early identification and risk stratification in DKD. Its association with renal fibrosis and its potential to predict DKD progression make it a valuable candidate for further investigation and validation in large-scale clinical studies. Integrating galectin-3 measurements into routine clinical practice may enhance the ability to identify individuals at high risk of DKD and enable timely interventions to prevent or slow the progression of this debilitating complication of diabetes.

GROWTH DIFFERENTIATION FACTOR-15 (GDF-15)

1. GDF-15: Biology and Function

Growth differentiation factor-15 (GDF-15) is a member of the transforming growth factor-beta (TGF-β) superfamily of cytokines. It is secreted as a stress-responsive protein in various tissues, including the kidneys, and plays a role in regulating cellular responses to injury, inflammation, and oxidative stress. GDF-15 is involved in diverse physiological and pathological processes, such as cell growth, differentiation, apoptosis, inflammation, and tissue repair.

2. GDF-15 in Kidney Disease

In the context of kidney disease, GDF-15 has emerged as a potential biomarker of renal injury and dysfunction. Studies have shown that GDF-15 expression is upregulated in the kidneys in response to various pathological conditions, including ischemia-reperfusion injury, acute kidney injury, and chronic kidney disease. The upregulation of GDF-15 in the kidneys is believed to be a protective response to mitigate tissue damage and promote repair processes.

3. GDF-15 as a Biomarker for Early Identification of DKD

GDF-15 has shown promise as a biomarker for the early identification of DKD. Clinical studies have reported elevated levels of GDF-15 in the blood and urine of DKD patients compared to individuals with diabetes but without kidney involvement. Importantly, GDF-15 levels have been found to be increased even in the early stages of DKD, before the onset of significant

albuminuria or decline in renal function. This suggests that GDF-15 may serve as an early marker of renal injury in DKD.

4. Mechanisms Underlying GDF-15's Role in DKD Progression

The exact mechanisms underlying the role of GDF-15 in DKD progression are not fully understood. However, studies have suggested several potential mechanisms. GDF-15 has been shown to possess anti-inflammatory and anti-fibrotic properties, which may help mitigate the pathological processes associated with DKD. It can suppress the activation of pro-inflammatory signaling pathways, inhibit the proliferation of fibroblasts, and modulate the production of extracellular matrix proteins.

GDF-15 may also exert renoprotective effects through its antioxidant properties. Oxidative stress plays a crucial role in the pathogenesis of DKD, and GDF-15 has been shown to attenuate oxidative stress-induced renal injury. Furthermore, GDF-15 may influence cellular responses to metabolic stress, such as mitochondrial dysfunction and metabolic reprogramming, which are implicated in DKD progression.

CONCLUSION

The early identification of diabetic kidney disease (DKD) is crucial for implementing timely interventions to prevent disease progression and reduce the burden of diabetes-related complications. Current diagnostic methods, such as measuring albuminuria and estimating glomerular filtration rate, may not accurately detect early-stage kidney damage. Therefore, there is a need for novel biomarkers that can provide early identification and risk stratification in DKD patients.

Galectin-3 and growth differentiation factor-15 (GDF-15) have emerged as potential biomarkers for the early identification of DKD. Galectin-3, an important mediator of fibrosis, has shown promise in predicting DKD progression and has been associated with histological features of renal damage. GDF-15, a stress-responsive cytokine, has been found to be elevated in DKD patients even in the early stages of the disease. It possesses anti-inflammatory, anti-fibrotic, and antioxidant properties, which may contribute to its Reno protective effects.

Integrating galectin-3 and GDF-15 measurements into routine clinical practice may enhance the ability to identify individuals at high risk of DKD and enable timely interventions. These biomarkers could potentially complement existing diagnostic markers and provide valuable information about the presence and severity of renal damage in DKD patients. Moreover, galectin-3 and GDF-15 may have utility in predicting DKD progression, as well as the risk of cardiovascular events and mortality.

REFERENCES

1. Sharma K., McCue P., Dunn S. R. (2011). Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol, 300(4), F811-9.

2. Macisaac, R. J., &Jerums, G. (2011). Diabetic kidney disease with and without albuminuria. CurrOpinNephrolHypertens, 20(3), 246-57.

3. Henderson, N. C., &Sethi, T. (2009). The regulation of inflammation by galectin-3. Immunol Rev, 230(1), 160-71.

4. Nakajima, K., Kho, D. H., Yanagawa, T., &Harazono, Y. (2010). Galectin-3 cleavage alters bone remodeling: different outcomes in breast and prostate cancer skeletal metastasis. Cancer Res, 70(15), 6264-73.

5. Barazzoni, R., GortanCappellari, G., Semolic, A., et al. (2018). Plasma levels of growth differentiation factor-15 significantly predict cardiac and extra-cardiac mortality in older men. Aging Cell, 17(2), e12771.

6. Lok, S. I., Winkens, B., Goldschmeding, R., et al. (2017). Circulating growth differentiation factor-15 correlates with myocardial fibrosis in patients with non-ischaemic dilated cardiomyopathy and decreases rapidly after left ventricular assist device support. Eur J Heart Fail, 19(11), 1423-1431.

7. Ziyadeh, F. N. (2004). Mediators of diabetic renal disease: the case for TGF-beta as the major mediator. J Am SocNephrol, 15(Suppl 1), S55-7.

8. Fioretto, P., &Mauer, M. (2007). Histopathology of diabetic nephropathy. SeminNephrol, 27(2), 195-207.

9. de Boer, I. H., Gao, X., Cleary, P. A., et al. (2011). Albuminuria changes and cardiovascular and renal outcomes in type 1 diabetes: the DCCT/EDIC study. Clin J Am SocNephrol, 6(9), 2366-73.

10. Ederhy, S., Di Angelantonio, E., Mallat, Z., et al. (2016). Galectin 3 in heart failure with preserved ejection fraction. Eur J Heart Fail, 18(6), 715-22.